Financial Data and Key Metrics Changes - Adjusted earnings per share for the third quarter were $1.86, exceeding guidance by $0.10 [5][31] - Total net revenues reached nearly $15.8 billion, reflecting high single-digit sales growth and beating expectations by approximately $300 million [5][31] - Adjusted gross margin was 83.9% of sales, with adjusted R&D expense at 14.3% and adjusted SG&A expense at 21.6% [31] - The adjusted operating margin ratio was 30.9% of sales, including a 17% unfavorable impact from acquired IPR&D expense [31] Business Line Data and Key Metrics Changes - Immunology revenues totaled approximately $7.9 billion, up 11.2% operationally, with SKYRIZI and RINVOQ showing combined sales growth of over 40% [11][12] - SKYRIZI global sales were $4.7 billion, reflecting operational growth of 46%, while RINVOQ revenues were nearly $2.2 billion, up 34.1% [11][12] - Oncology revenues were nearly $1.7 billion, remaining relatively flat year-over-year, with VENCLEXTA and newer products offsetting declines from IMBRUVICA [15][16] - Aesthetics sales were approximately $1.2 billion, down 4.2% operationally, with BOTOX and JUVÉDERM experiencing declines [16][17] - Neuroscience revenues exceeded $2.8 billion, up 19.6% operationally, driven by strong performance from UBRELVY, QULIPTA, and VRAYLAR [18][19] Market Data and Key Metrics Changes - The U.S. aesthetics market is currently facing challenges, with overall consumer sentiment low, impacting discretionary spending [17] - The IL-23 market is expanding rapidly, with SKYRIZI and RINVOQ maintaining strong positions despite competition from TREMFYA [49][50] - The Parkinson's disease treatment market is seeing significant uptake for VYALEV, with a competitive advantage over ONAPGO due to its 24-hour coverage [74][75] Company Strategy and Development Direction - AbbVie is focused on pipeline advancement across immunology, oncology, neuroscience, and aesthetics, with approximately 90 programs in development [7][8] - The company is investing heavily in R&D, anticipating $9 billion in adjusted R&D expense for 2025, to support numerous pipeline opportunities [7][9] - AbbVie is committed to external innovation, including recent acquisitions to enhance its psychiatry and immunology pipelines [8][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to adapt to changes in the PBM model and emphasized the importance of differentiated medicines [39][44] - The outlook for 2026 remains strong, with expectations for continued growth driven by the performance of SKYRIZI, RINVOQ, and the neuroscience portfolio [52][54] - Management highlighted the potential for significant growth in the neuroscience franchise, particularly with emerging products like tavapadon and VYALEV [61][78] Other Important Information - AbbVie announced a 5.5% increase in its quarterly cash dividend, reflecting a commitment to delivering a sustainable dividend [9][34] - The company has executed approximately 30 deals since the beginning of 2024, focusing on external innovation across key growth areas [35] Q&A Session Summary Question: Implications of the new PBM model and IRA price negotiations for VRAYLAR and LINZESS - Management emphasized the adaptability of AbbVie to changes in the PBM model and stated that the outcomes of IRA negotiations would not impact long-term guidance [39][44] Question: Competitive dynamics in the IL-23 market and outlook for 2026 - Management noted strong growth for SKYRIZI and RINVOQ, with confidence in maintaining competitive positions despite the entry of TREMFYA [49][50][54] Question: Long-term outlook for SKYRIZI and RINVOQ and market stress in aesthetics - Management indicated that the long-term guidance for SKYRIZI and RINVOQ may be exceeded, while also addressing challenges in the aesthetics market and plans for revitalization [59][63]

Core Viewpoint - AbbVie reported quarterly earnings of $1.86 per share, exceeding the Zacks Consensus Estimate of $1.77 per share, but down from $3 per share a year ago, indicating a significant year-over-year decline in earnings [1][2] Financial Performance - AbbVie achieved revenues of $15.78 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.20% and showing an increase from $14.46 billion in the same quarter last year [2] - The company has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - AbbVie shares have increased approximately 28.4% since the beginning of the year, outperforming the S&P 500's gain of 16% [3] - The immediate price movement of AbbVie’s stock will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $3.33, with expected revenues of $16.32 billion, and for the current fiscal year, the EPS estimate is $10.80 on revenues of $60.68 billion [7] - The estimate revisions trend for AbbVie was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Large Cap Pharmaceuticals industry, to which AbbVie belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of AbbVie’s stock may also be influenced by the overall outlook for the industry [8]

Financial Performance - AbbVie reported adjusted earnings per share of $1.86, exceeding guidance by $0.10 [4][28] - Total net revenues reached nearly $15.8 billion, reflecting an operational growth of 8.4% [28] - Adjusted gross margin was 83.9% of sales, with adjusted R&D expense at 14.3% and adjusted SG&A expense at 21.6% [28] Business Line Performance - Immunology revenues totaled approximately $7.9 billion, up 11.2% operationally, driven by SKYRIZI and RINVOQ, which saw sales growth of 46% and 34.1% respectively [10][11] - Oncology revenues were nearly $1.7 billion, remaining flat year-over-year, with VENCLEXTA and newer products offsetting declines from IMBRUVICA [13][14] - Neuroscience revenues exceeded $2.8 billion, up 19.6%, with strong performances from Ubrelvy, Qulipta, and Vraylar [17][18] - Aesthetics sales were approximately $1.2 billion, down 4.2%, impacted by challenging market conditions [14][15] Market Dynamics - SKYRIZI and RINVOQ are gaining significant market share in gastroenterology, capturing nearly 50% of newer switching Crohn's patients in the U.S. [10][11] - Humira's global sales declined by 55.7% to $993 million due to biosimilar competition [13] - The aesthetics market is facing low consumer sentiment and inflation concerns, leading to below-expected category growth [16] Strategic Direction - AbbVie is raising its 2025 outlook for the third time this year, indicating strong business performance and pipeline advancement [4][5] - The company plans to invest at least $10 billion in the U.S. over the next decade, with ongoing construction of new manufacturing sites [8] - AbbVie is focusing on expanding its pipeline with approximately 90 programs across various therapeutic areas, including immunology, oncology, and neuroscience [5][6] Management Commentary - Management expressed confidence in the company's ability to adapt to changes in the PBM model and emphasized the importance of differentiated medicines for growth [35][36] - The management highlighted the strong performance of SKYRIZI and RINVOQ, with expectations for continued growth despite challenges from Humira erosion [46][52] Other Important Information - AbbVie announced a 5.5% increase in its quarterly cash dividend, reflecting a commitment to delivering sustainable returns to shareholders [8][31] - The company has executed approximately 30 deals since the beginning of 2024, focusing on external innovation to drive growth [32] Q&A Session Summary Question: Implications of new PBM model and IRA price negotiations - Management indicated that AbbVie's performance is driven by differentiated medicines and strong execution, allowing adaptability to changes in the PBM model [35][36] - The outcomes of IRA price negotiations for Vraylar and Linzess will not impact long-term guidance [38] Question: Competitive dynamics in the IL-23 market - Management expressed confidence in SKYRIZI's growth and its leadership position in IBD, despite competition from Tremfya [42][44] - The IL-23 class is expanding rapidly, benefiting all players in the market [42] Question: 2026 outlook and business dynamics - Management noted strong performance across the neuroscience portfolio and anticipates continued growth despite headwinds from Humira erosion [46][47] Question: Long-term guidance for SKYRIZI and RINVOQ - Management indicated that the combined guidance for SKYRIZI and RINVOQ for 2025 has been raised significantly, suggesting potential for exceeding long-term expectations [51][52] Question: Market conditions for aesthetics products - Management acknowledged challenges in the U.S. aesthetics market but emphasized ongoing investments to revitalize the segment [56][57]

Core Insights - AbbVie is experiencing significant growth in its immunology drugs, particularly Skyrizi and Rinvoq, which are offsetting declines from Humira and its aesthetics division [2][4][5] - The company reported third-quarter sales of $15.78 billion, exceeding expectations, with a notable operational growth of 8.4% [4] - AbbVie raised its full-year earnings guidance, now expecting adjusted earnings of $10.61 to $10.65 per share, which is above analyst projections [7] Financial Performance - Skyrizi generated $4.71 billion in sales, a 47% increase, while Rinvoq sales reached $2.18 billion, growing 35% [2] - Overall sales for AbbVie grew more than 9% year-over-year, surpassing the expected $15.59 billion [4] - Adjusted earnings per share were reported at $1.86, despite a 38% decline due to a tax charge, still beating projections of $1.77 [4] Product Performance - Humira sales fell to $993 million, facing competition from lower-cost biosimilars [5] - Sales from Botox and Juvederm declined nearly 4% to $1.19 billion, missing expectations [5] - The neuroscience segment, which includes Botox, saw a 20% increase in sales to $2.84 billion, exceeding forecasts [6] Future Outlook - Analysts are optimistic about the long-term growth potential from AbbVie's Parkinson's disease franchise and late-stage antibody drug conjugates [8] - AbbVie stock is currently finding support near its 21-day moving average, indicating potential stability [8]

Core Insights - AbbVie raised its 2025 profit forecast due to strong sales of newer immunology drugs Skyrizi and Rinvoq, which helped boost third-quarter results above estimates [1][3] - The company is facing challenges in its aesthetics products portfolio, particularly with Botox, which saw a 3.7% decline in sales from the previous year [2] - Concerns regarding the economy and inflation are impacting customer spending, leading to lower growth expectations globally [3] Financial Performance - AbbVie now expects adjusted annual profit per share to be between $10.61 and $10.65, an increase from previous expectations of $10.38 to $10.58 [3] - The company reported quarterly sales of $15.78 billion, exceeding analysts' average estimate of $15.59 billion [3] - Quarterly profit per share was $1.86, surpassing estimates of $1.77 per share [5] Product Sales - Global sales of Humira, AbbVie's flagship arthritis treatment, were $993 million in the third quarter, falling short of estimates of $1.15 billion [4] - Skyrizi generated sales of $4.71 billion, exceeding estimates of $4.44 billion, while Rinvoq sales reached $2.18 billion, topping estimates of $2.12 billion [4]

Group 1 - Energy giants Exxon Mobil Corporation and Chevron Corporation are highlighted as leading companies in the pre-market on a busy Friday [1] - AbbVie Inc. is also mentioned as a significant player in the pre-market activity [1] - Upcoming earnings reports include Palantir Technologies Inc. on Monday, followed by major companies like Shopify Inc., Uber Technologies Inc., Pfizer Inc., and Advanced Micro Devices Inc. on Tuesday [1] - Wednesday will feature technology companies such as Applovin Corporation, QUALCOMM Incorporated, and Arm Holdings plc after market [1] - AstraZeneca PLC and ConocoPhillips will report pre-market on Thursday, with KKR & Co. Inc. and Constellation Energy Corporation following on Friday [1]

Core Viewpoint - The article emphasizes the importance of generating a lifetime stream of passive income for investors at any stage of their financial journey [1] Group 1 - Passive income can be beneficial for both new investors and those approaching retirement [1]

Core Viewpoint - AbbVie has raised its full-year adjusted earnings outlook despite facing profit pressures due to increased expenses in the third quarter [1] Financial Performance - The company reported a rise in adjusted earnings outlook for the full year, indicating confidence in future performance [1] - Profit was impacted by higher expenses during the third quarter, suggesting challenges in cost management [1]

Revenue attributed to AbbVie's oncology and aesthetics portfolio declined in the quarter. ...

Group 1 - AbbVie reported a net profit of $15.78 billion for the third quarter, exceeding expectations of $15.59 billion [1] - The adjusted earnings per share for the third quarter were $1.86 [1] - AbbVie raised its full-year adjusted earnings per share guidance to $10.61-$10.65, up from the previous estimate of $10.38-$10.58 [1]